Towerview LLC Acquires 35,000 Shares of Alumis Inc. (NASDAQ:ALMS)

Towerview LLC grew its holdings in shares of Alumis Inc. (NASDAQ:ALMS) by 9.2% in the 4th quarter, Holdings Channel reports. The fund owned 415,000 shares of the company’s stock after buying an additional 35,000 shares during the period. Alumis accounts for 2.3% of Towerview LLC’s investment portfolio, making the stock its 8th largest holding. Towerview LLC’s holdings in Alumis were worth $3,262,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ALMS. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alumis during the fourth quarter worth $79,000. JPMorgan Chase & Co. bought a new stake in Alumis during the 3rd quarter worth $191,000. Barclays PLC acquired a new position in Alumis in the 3rd quarter worth about $197,000. Geode Capital Management LLC bought a new position in Alumis in the third quarter valued at about $3,266,000. Finally, State Street Corp acquired a new stake in shares of Alumis during the third quarter valued at about $866,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ALMS shares. Oppenheimer started coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. HC Wainwright reduced their price target on shares of Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Robert W. Baird assumed coverage on shares of Alumis in a report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Baird R W upgraded shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $26.57.

Alumis Stock Performance

ALMS opened at $4.67 on Friday. The company has a fifty day moving average price of $6.81 and a 200-day moving average price of $9.50. Alumis Inc. has a one year low of $4.46 and a one year high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.